Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) has received an average rating of "Hold" from the twelve brokerages that are covering the stock, Marketbeat reports. Eight research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $78.22.

Several research firms have recently commented on TPTX. SVB Leerink lowered Turning Point Therapeutics from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $101.00 to $76.00 in a research note on Monday, June 13th. Guggenheim set a $76.00 target price on shares of Turning Point Therapeutics in a report on Monday, June 20th. Cowen downgraded shares of Turning Point Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, June 6th. Wells Fargo & Company downgraded shares of Turning Point Therapeutics from an "overweight" rating to an "equal weight" rating and set a $76.00 target price for the company. in a report on Friday, June 3rd. Finally, Cowen downgraded shares of Turning Point Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, June 6th.

Insider Buying and Selling at Turning Point Therapeutics

In other Turning Point Therapeutics news, CFO Paolo Tombesi sold 1,183 shares of the stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $74.94, for a total transaction of $88,654.02. Following the completion of the transaction, the chief financial officer now owns 28,700 shares of the company's stock, valued at approximately $2,150,778. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 8.60% of the company's stock.

Institutional Inflows and Outflows

Turning Point Therapeutics Trading Up 0.7 %

Shares of TPTX opened at $76.01 on Monday. The firm has a market cap of $3.81 billion, a PE ratio of -11.02 and a beta of -0.18. Turning Point Therapeutics has a 1-year low of $23.77 and a 1-year high of $82.20. The firm has a fifty day simple moving average of $75.49 and a two-hundred day simple moving average of $54.27.

Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) last posted its quarterly earnings data on Monday, August 8th. The company reported ($2.48) EPS for the quarter, missing the consensus estimate of ($1.78) by ($0.70). The firm had revenue of $0.12 million during the quarter, compared to analysts' expectations of $2.27 million. Turning Point Therapeutics's quarterly revenue was down 97.7% compared to the same quarter last year. During the same period last year, the business earned ($1.14) EPS. As a group, research analysts forecast that Turning Point Therapeutics will post -7.69 EPS for the current fiscal year.

Turning Point Therapeutics Company Profile

(Get Rating)

Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

See Also

• Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
• Kroger's is Your One-Stop Consumer Staples Stock
• Adobe Perfects the Art of the Faceplant for Investors
• Tax Credits are the Incentives in the Inflation Reduction Act
• 3 Banks Worth Considering For Q4
• Stock Market: 3 Islands Of Strength In A Sea Of Red

Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.